Seres Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Seres Therapeutics, Inc. (MCRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $7.79 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-05
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $7.79, a 43.30% decline year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $10.34, a 41.22% decline year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $10.18, a 22.05% decline year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $13.74, a 27.80% decline year-over-year.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $13.30, a 28.42% decline from fiscal 2024.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $18.58, a 79.44% decline from fiscal 2023.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $90.37, a 1534.18% increase from fiscal 2022.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.53, a 63.93% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.79 10-Q · filed 2026-08-05 | |||||||
| 2026-03-31 | $7.79 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | $13.30 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | $10.34 10-Q · filed 2025-11-05 | $13.30 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | $10.18 10-Q · filed 2026-08-05 | $13.49 10-Q · filed 2026-08-05 | ||||||
| 2025-03-31 | $13.74 10-Q · filed 2026-05-05 | |||||||
| 2024-12-31 | $18.58 10-K · filed 2026-03-12 | $0.93 10-K · filed 2025-03-13 | ||||||
| 2024-09-30 | $17.59 10-Q · filed 2025-11-05 | $0.88 10-Q · filed 2024-11-13 | $18.58 10-Q · filed 2025-11-05 | $0.93 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $13.06 10-Q · filed 2025-08-06 | $0.65 10-Q · filed 2024-08-13 | $18.67 10-Q · filed 2025-08-06 | $0.93 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $19.03 10-Q · filed 2025-05-07 | $0.95 10-Q · filed 2024-05-08 | ||||||
| 2023-12-31 | $90.37 10-K · filed 2026-03-12 | $4.51 10-K · filed 2024-03-05 | ||||||
| 2023-09-30 | $3.14 10-Q · filed 2024-11-13 | $4.52 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | $4.54 10-Q · filed 2024-08-13 | $4.56 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $4.56 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | $5.53 10-K · filed 2025-03-13 | |||||||
| 2022-09-30 | $4.07 10-Q · filed 2023-11-02 | $5.53 10-Q · filed 2023-11-02 | ||||||
| 2022-06-30 | $3.50 10-Q · filed 2023-08-08 | $5.60 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $5.90 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | $15.33 10-K · filed 2024-03-05 | |||||||
| 2021-09-30 | $10.08 10-Q · filed 2022-11-02 | $17.89 10-Q · filed 2022-11-02 | ||||||
| 2021-06-30 | $16.26 10-Q · filed 2022-08-03 | $18.51 10-Q · filed 2022-08-03 | ||||||
| 2021-03-31 | $19.33 10-Q · filed 2022-05-04 | |||||||
| 2020-12-31 | $5.08 10-K · filed 2023-03-07 | |||||||
| 2020-09-30 | $18.12 10-Q · filed 2021-11-10 | $3.03 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $2.41 10-Q · filed 2021-08-03 | $2.17 10-Q · filed 2021-08-03 | ||||||
| 2020-03-31 | $2.06 10-Q · filed 2021-05-04 | |||||||
| 2019-12-31 | $4.13 10-K · filed 2022-03-01 | |||||||
| 2019-09-30 | $2.12 10-Q · filed 2020-11-09 | $5.67 10-Q · filed 2020-11-09 | $4.24 10-Q · filed 2019-11-05 | |||||
| 2019-06-30 | $2.38 10-Q · filed 2020-07-28 | $4.34 10-Q · filed 2020-07-28 | ||||||
| 2019-03-31 | $4.60 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $6.53 10-K · filed 2021-03-02 | |||||||
| 2018-09-30 | $5.67 10-Q · filed 2019-11-05 | $6.83 10-Q · filed 2019-11-05 | ||||||
| 2018-06-30 | $6.89 10-Q · filed 2019-08-06 | $5.82 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | $7.02 10-Q · filed 2019-05-02 | |||||||
| 2017-12-31 | $7.07 10-K · filed 2020-03-02 | |||||||
| 2017-09-30 | $8.43 10-Q · filed 2018-11-08 | $7.06 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | $7.44 10-Q · filed 2018-08-02 | $6.98 10-Q · filed 2018-08-02 | ||||||
| 2017-03-31 | $6.93 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | $18.45 10-K · filed 2019-03-06 | |||||||
| 2016-09-30 | $12.45 10-Q · filed 2017-11-08 | $18.93 10-Q · filed 2017-11-08 | ||||||
| 2016-06-30 | $20.64 10-Q · filed 2017-08-03 | $19.87 10-Q · filed 2017-08-03 | ||||||
| 2016-03-31 | $19.59 10-Q · filed 2017-05-04 | |||||||
| 2015-12-31 | $14.56 10-K · filed 2018-03-08 | |||||||
| 2015-09-30 | $29.25 10-Q · filed 2015-11-12 | $13.00 10-Q · filed 2015-11-12 | ||||||
| 2015-06-30 | $13.40 10-Q · filed 2015-08-10 | $12.18 10-Q · filed 2015-08-10 | ||||||
| 2014-12-31 | $4.25 10-K · filed 2017-03-16 | |||||||
| 2013-12-31 | $0.35 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |